Evidence map›Paper›PMID 38123146›Full record

ArticleJournal of cachexia, sarcopenia and muscle2024

Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma.

Andrea N Riner, Kelly M Herremans, Vignesh Vudatha, Song Han, Xufeng Qu, Jinze Liu, Nitai Mukhopadhyay, Devon C Freudenberger, Thomas J George, Sarah M Judge and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Andrea N RinerDepartment of Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.ORCID 0000-0003-2088-5400
Kelly M HerremansDepartment of Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.
Vignesh VudathaDepartment of Surgery, Virginia Commonwealth University, Richmond, Virginia, USA.
Song HanDepartment of Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.
Xufeng QuDepartment of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA.
Jinze LiuDepartment of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA.
Nitai MukhopadhyayDepartment of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA.
Devon C FreudenbergerDepartment of Surgery, Virginia Commonwealth University, Richmond, Virginia, USA.
Thomas J GeorgeDepartment of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
Sarah M JudgeDepartment of Physical Therapy, University of Florida Health Science Center, Gainesville, Florida, USA.
Andrew R JudgeDepartment of Physical Therapy, University of Florida Health Science Center, Gainesville, Florida, USA.
Steven J HughesDepartment of Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.
Jose G TrevinoDepartment of Surgery, Virginia Commonwealth University, Richmond, Virginia, USA.ORCID 0000-0002-0265-8151
Virginia Commonwealth University · USUniversity of Florida · USUniversity of Florida Health · US

Funding

Tissue Modeling & Drug Development Shared Resources CoreU54CA233444 · NCI · UNIVERSITY OF FLORIDA · PI Chanita A. Hughes-Halbert, Sulma Ibrahim Mohammed · 2018 to 2026
$12.1M
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERSU01DK108320 · NIDDK · UNIVERSITY OF FLORIDA · PI CUSI, KENNETH, FORSMARK, CHRISTOPHER E · 2015 to 2024
$4.6M
FOXO signaling and skeletal muscle atrophyR01AR060209 · NIAMS · UNIVERSITY OF FLORIDA · PI JUDGE, ANDREW ROBERT · 2011 to 2021
$4.2M
Training Program for Applied Research and Development in Genomic MedicineT32HG008958 · NHGRI · UNIVERSITY OF FLORIDA · PI Larisa Humma Cavallari, Stephen E. Kimmel · 2018 to 2026
$3.8M
Training Program in Cancer Prevention and Control and Cancer Health Equity (CPC-CHE)T32CA093423 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Bernard F Fuemmeler, Oxana G Palesh · 2018 to 2026
$3.0M
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancerR01CA242003 · NCI · UNIVERSITY OF FLORIDA · PI TREVINO, JOSE G., ZHENG, GUANGRONG · 2019 to 2023
$2.6M
NCI NIH HHS R01 CA242003NCI NIH HHS R01CA242003NCI NIH HHS T32 CA093423NCI NIH HHS T32 CA093423-13NCI NIH HHS U54 CA233444NCI NIH HHS U54CA233444NCI NIH HHS U54CA233444-03S1NHGRI NIH HHS T32 HG008958NIAMS NIH HHS R01 AR060209NIAMS NIH HHS R01AR060209NIDDK NIH HHS U01 DK108320NIDDK NIH HHS U01DK108320-06
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is highly associated with cachexia and weight loss, which is driven by the tumour's effect on the body. Data are lacking on differences in these metrics based on PDAC anatomic location. We hypothesize that the primary tumour's anatomic region influences the prevalence and severity of unintentional weight loss.

methodsTreatment naïve patients with PDAC who underwent pancreatectomy at a single institution between 2012 and 2020 were identified retrospectively. Patients with pancreatic head or distal tumours were matched by sex, age, N and T stage. Serologic and anthropometric variables were obtained at the time of diagnosis. Skeletal muscle index (SMI), muscle radiation attenuation (MRA) and adiposity were measured. The primary outcome was presence of significant weight loss [>5% body weight (BW) loss in past 6 months]. Signed rank tests, Cochran Mantel Haenszel tests and Kaplan-Meier survival analysis are presented. RNA-seq of tumours was performed to explore enriched pathways related to cachexia and weight loss.

resultsPancreatic head tumours (n = 24) were associated with higher prevalence (70.8% vs. 41.7%, P = 0.081) and degree of weight loss (7.9% vs. 2.5%, P = 0.014) compared to distal tumours (n = 24). BMI (P = 0.642), SMI (P = 0.738) and MRA (P = 0.478) were similar between groups. Combining BW loss, SMI and MRA into a composite score, patients with pancreatic head cancers met more criteria associated with poor prognosis (P = 0.142). Serum albumin (3.9 vs. 4.4 g/dL, P = 0.002) was lower and bilirubin (4.5 vs. 0.4 mg/dL, P < 0.001) were higher with pancreatic head tumours. Survival differed by tumour location (P = 0.014) with numerically higher median overall survival with distal tumours (11.1 vs. 21.8 months; P = 0.066). Transcriptomic analysis revealed inactivation of appetite stimulation, weight regulation and nutrient digestion/metabolism pathways in pancreatic head tumours.

conclusionsResectable pancreatic head PDAC is associated with higher prevalence of significant weight loss and more poor prognosis features. Pancreaticobiliary obstruction and hypoalbuminemia in patients with head tumours suggests compounding effects of nutrient malabsorption and systemic inflammation on molecular drivers of cachexia, possibly contributing to shorter survival. Therefore, PDAC-associated cachexia is a heterogenous syndrome, which may be influenced by the primary tumour location. Select patients with resectable pancreatic head tumours may benefit from nutritional rehabilitation to improve outcomes.

Indexed as

Carcinoma, Pancreatic DuctalHead and Neck NeoplasmsPancreatic NeoplasmsCachexiaGene Expression ProfilingHumansRetrospective StudiesAdipose tissueMalabsorptionNutritionPancreaticobiliary obstructionSkeletal muscleWeight loss

Identifiers

PMID38123146
PMCPMC10834348
OpenAlexW4390030182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.